2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 522

Patient-Provider Discordance in Global Assessments of Disease Activity in Patients with Rheumatoid Arthritis: Persistence, Predictors and Impact
Abstract Number: 523

Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Abstract Number: 524

A Self-Determination Theory Based Intervention to Increase Levels of Cardiorespiratory Fitness, Self-Determined Motivation, Physical Activity and Improve Health Outcomes Among Patients Living with Rheumatoid Arthritis
Abstract Number: 525

Predictors of Health Care Drop-out in an Inception Cohort of Patients with Early Onset Rheumatoid Arthritis
Abstract Number: 526

Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era
Abstract Number: 527

The Summed Bilateral Elbow Extension Angle in Rheumatoid Arthritis Correlates with the DAS28-CRP(4) and May be an Independent Marker of Bad Prognosis
Abstract Number: 528

Assessment of Metacarpal Head Bone Microarchitecture According to Presence or Not of Inflammation in Rheumatoid Arthritis Patients with Low Disease Activity
Abstract Number: 529

The Relationship Between Promis and CDAI Scores, Disease Duration, Age and Gender in Patients with Rheumatoid Arthritis
Abstract Number: 530

Importance of Functional and Utility Evaluation on Disease Activity Level in Rheumatoid Arthritis: Interrelations and Predictive Value
Abstract Number: 531

Disease Activity and Physical Fatigue As Related to Adherence and Health Literacy in Patients with Rheumatoid Arthritis
Abstract Number: 532

The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 533

What Proportion of Patients Fail to Achieve CDAI and SDAI Remission Based on Physician Global Assessment? an Analysis from the Prospective, Observational Registry
Abstract Number: 534

Discordance Between Physician-Stated Remission and 28-Joint Disease Activity Score (DAS28)-Defined Remission in Rheumatoid Arthritis Patients
Abstract Number: 535

Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference
Abstract Number: 536

Precision Medicine in Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis on the Diagnostic Accuracy of Anti-CCP Tests for the Diagnosis of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].